Centre Hospitalier du Rouvray
9
1
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
11.1%
1 terminated/withdrawn out of 9 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Understanding and Treating Severe and Resistant Pathological Aggression: Using Deep Brain Stimulation to Treat Resistant Aggression
Role: collaborator
NEUROIMAGING OF ADOLESCENT BORDERLINE PERSONALITY DISORDER WITH AND WITHOUT POST-TRAUMATIC STRESS DISORDER
Role: collaborator
Clinical, Cognitive and Neural Effects of Potentiation of ECT by rTMS in Treatment-Resistant Depression
Role: lead
Subthalamic Nucleus Stimulation Electrode and Psychiatric Lesion Effects in Parkinson's Disease
Role: lead
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
Role: collaborator
Clinical Trial on Efficacy of rTMS to Improve ECT in Treatment-Resistant Depression
Role: lead
ECT in Ultra-resistant Schizophrenia
Role: lead
Transcranial Magnetic Stimulation Study of Cortical Excitability as Marker of Antidepressant Response: EXCIPSY Study
Role: lead
Effects of Cathodal tDCS on Executive Functions in Autism
Role: lead
All 9 trials loaded